The abstract is read at the publisher; the summary is JClub's.
SSRI use, compared with benzodiazepines, is linked to lower 2-year all-cause mortality (23.5% vs 34.4%; HR 0.627, 95% CI 0.549–0.716) in ICI-treated solid-tumor patients with depression or anxiety.
- Why it matters: It is unknown whether preclinical SERT (SLC6A4) immune effects translate into clinical benefit for patients receiving immune checkpoint inhibitors, despite uncertainty about real-world confounding.
- What they did: Using a target trial emulation in TriNetX (over 187 million patients), propensity score matched 1,567 SSRI–BZD pairs at first ICI administration, with 2-year overall survival as the primary outcome; TCGA transcriptomics (8,272 samples, 20 tumor types) assessed SLC6A4 and immune infiltration.
- The result: SSRI use was associated with fewer newly coded distant metastases (HR 0.629, 95% CI 0.487–0.811) and all five individually analyzable SSRIs showed lower mortality (HR 0.61–0.71); in TCGA, SLC6A4 expression inversely correlated with T-cell inflammation in 13 of 20 cancers.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.